Relapsed or refractory acute myeloid leukemia
Clinical trials for Relapsed or refractory acute myeloid leukemia explained in plain language.
Never miss a new study
Get alerted when new Relapsed or refractory acute myeloid leukemia trials appear
Sign up with your email to follow new studies for Relapsed or refractory acute myeloid leukemia, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug aims at CD123 to fight Hard-to-Treat blood cancers
Disease control Not yet recruitingResearchers are testing an experimental drug called ORM-1153 in adults whose acute myeloid leukemia (AML) or other blood cancer has returned or stopped responding to treatment. The drug targets CD123, a protein found on the surface of these cancer cells. Participants receive ORM-…
Matched conditions: RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
Phase 1 • Sponsor: Orum Therapeutics USA, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a menin-blocking drug outsmart stubborn leukemia?
Disease control Not yet recruitingThis trial is testing an experimental drug called S243249, which blocks a protein called menin, in people whose acute leukemia has come back or not responded to standard treatment. The study focuses on patients with specific genetic changes (KMT2A or NUP98 translocations, or NPM1…
Matched conditions: RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
Phase 1/2 • Sponsor: Servier • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a new drug take on multiple tough cancers?
Disease control Not yet recruitingThis early-stage trial tests an investigational drug called CBX-663 in adults with certain advanced cancers that have not responded to standard treatment or have returned. The study includes people with blood cancers (like AML, MDS, or CMML), advanced solid tumors, or a type of b…
Matched conditions: RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
Phase 1 • Sponsor: Crossbow Therapeutics, Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC